The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The global Tax Tech Market will grow from USD 18.53 billion in 2024 to USD 36.72 billion by 2030 at a compounded annual ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, reveals that while free, easy product returns are paramount for consumer loyalty, they ...

The Israeli spyware company blacklisted over human rights concerns has hired the firm to provide strategic advice on cyber policy issues.

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...